168TiP KEYNOTE-A86: Phase III, randomized, open-label study of first-line subcutaneous (SC) vs intravenous (IV) pembrolizumab with platinum doublet chemotherapy in metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC). - Halmos, B.; Cobb, P.; Johnson, M.L.; Jain, L.; Kim, S.J.; Saraf, S.; Lala, M.; Kurata, T. (Annals of Oncology, 2021)